Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-23T10:18:03.142Z Has data issue: false hasContentIssue false

Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent

Published online by Cambridge University Press:  09 February 2024

Jeffrey R. Strawn  and
Stephen M. Stahl
Jeffrey R. Strawn
Affiliation:
University of Cincinnati, Ohio
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Which of the following is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bipolar mania in adolescents?

Type
Chapter
Information
Case Studies: Stahl's Essential Psychopharmacology
Children and Adolescents
 , pp. 65 - 76
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

DelBello, M. P., Strawn, J. R., Duran, L. P. Recognition and management of second-generation antipsychotic-associated adverse effects. J Am Acad Child Adolesc Psychiatry 2017; 56: S135. https://doi.org/10.1016/j.jaac.2017.07.509Google Scholar
Dogterom, P., Riesenberg, R., de Greef, R., et al. Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Design Dev Ther 2018; 12: 2677–93. https://doi.org/10.2147/DDDT.S171475Google Scholar
Findling, R. L., Lingler, J., Rowles, B. M., et al. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol 2008; 18: 615–21. https://doi.org/10.1089/cap.2008.018Google Scholar
Findling, R. L., Landbloom, R. P., Mackle, M., et al. Safety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2015a; 25: 384–96. https://doi.org/10.1089/cap.2015.0027Google Scholar
Findling, R. L., Landbloom, R. L., Szegedi, A., et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry 2015b; 54: 1032–41. https://doi.org/10.1016/j.jaac.2015.09.007Google Scholar
Findling, R. L., Earley, W., Suppes, T., et al. Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. Neuropsychiatr Dis Treat 2018; 14: 1941–52. https://doi.org/10.2147/NDT.S165743Google Scholar
McNamara, R. K., Strawn, J. R. Role of long-chain omega-3 fatty acids in psychiatric practice. PharmaNutrition 2013; 1: 41–9. https://doi.org/10.1016/j.phanu.2012.10.004Google Scholar
McNamara, R. K., Strimpfel, J., Jandacek, R. et al. Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder. PharmaNutrition 2014; 2: 38–46. https://doi.org/10.1016/j.phanu.2014.02.002Google Scholar
Posner, K., Brown, G. K., Stanley, B., et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266–77. https://doi.org/10.1176/appi.ajp.2011.10111704Google Scholar
Stahl, S., Grady, M. M., Muntner, N. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5th edn. Cambridge, UK: Cambridge University Press, 2021.Google Scholar
Strawn, J. R., DelBello, M. P. Recognizing and managing side effects of second-generation antipsychotics. J Am Acad Child Adolesc Psychiatry 2018; 57: S85. PMID: 16001096.Google Scholar
Strawn, J. R., Adler, C. M., McNamara, R. K., et al. Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study. Bipolar Disord 2014; 16: 523–30. https://doi.org/10.1111/bdi.12113Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×